TARS — Tarsus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.47bn
- $3.09bn
- $451.36m
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)
Deals of the day-Mergers and acquisitions
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
Tarsus Pharmaceuticals Q2 sales beat estimates, lifts 2026 XDEMVY sales outlook
Brief: Tarsus Pharmaceuticals Q2 EPS USD -0.43
U.S. STOCKS ON THE MOVE-Kroger, Meta, Sable
Brief: Culper Research Says We Are Short Tarsus Pharmaceuticals
Brief: Tarsus And John Cena Partner To Raise Awareness Of Demodex Blepharitis, A Common Eyelid Disease Affecting Approximately 25 Million Americans
Tarsus Pharma Q1 revenue jumps on XDEMVY sales
Brief: Tarsus Doses First Participant In Calliope, A Phase 2 Clinical Trial Of Tp-05 (Lotilaner)
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla
Tarsus rises as China approval unlocks $15 million milestone for eye drug
Tarsus Pharmaceuticals beats Q4 revenue estimates
Brief: Tarsus Pharmaceuticals Q4 EPS USD -0.2
Tarsus Pharma Q3 revenue beats estimates, driven by XDEMVY sales